- 現金殖利率: N/A、總殖利率: 0、5年平均現金配發率: N/A
- 要留意資產負債表的未分配盈餘和配息能力, 如果為負值, 可能會無法發放股利
- 股利有2個稅要支出, 分別是綜合所得稅和健保補充保費(單筆股利達2萬元以上, 課2.11%)
| EPS YoY | 現金股利 YoY | 股票股利 YoY | 現金配發率 YoY | 股票配發率 YoY | 全部配發率 YoY | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023 (10) | -0.77 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
| 2022 (9) | -1.07 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
| 2021 (8) | -1.87 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
| 2020 (7) | -0.73 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
| 2019 (6) | -2.30 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
| 2018 (5) | -1.28 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
| 2017 (4) | -2.10 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
| 2016 (3) | -1.14 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
| EPS QoQ YoY | 本業EPS QoQ YoY | 累計EPS QoQ YoY | |||||||
|---|---|---|---|---|---|---|---|---|---|
| 24Q3 (20) | -0.14 | -40.0 | -600.0 | -0.17 | -6.25 | -1600.0 | -0.31 | -82.35 | 41.51 |
| 24Q2 (19) | -0.10 | -66.67 | 47.37 | -0.16 | -14.29 | 33.33 | -0.17 | -183.33 | 66.67 |
| 24Q1 (18) | -0.06 | 75.0 | 81.25 | -0.14 | -40.0 | 46.15 | -0.06 | 92.21 | 81.25 |
| 23Q4 (17) | -0.24 | -1100.0 | -60.0 | -0.10 | -900.0 | -211.11 | -0.77 | -45.28 | 28.04 |
| 23Q3 (16) | -0.02 | 89.47 | 85.71 | -0.01 | 95.83 | 95.45 | -0.53 | -3.92 | 42.39 |
| 23Q2 (15) | -0.19 | 40.62 | 36.67 | -0.24 | 7.69 | -14.29 | -0.51 | -59.38 | 33.77 |
| 23Q1 (14) | -0.32 | -113.33 | 31.91 | -0.26 | -388.89 | 31.58 | -0.32 | 70.09 | 31.91 |
| 22Q4 (13) | -0.15 | -7.14 | 87.29 | 0.09 | 140.91 | 110.0 | -1.07 | -16.3 | 42.78 |
| 22Q3 (12) | -0.14 | 53.33 | 54.84 | -0.22 | -4.76 | 15.38 | -0.92 | -19.48 | -35.29 |
| 22Q2 (11) | -0.30 | 36.17 | 23.08 | -0.21 | 44.74 | 36.36 | -0.77 | -63.83 | -108.11 |
| 22Q1 (10) | -0.47 | 60.17 | -2450.0 | -0.38 | 57.78 | -18.75 | -0.47 | 74.87 | -2450.0 |
| 21Q4 (9) | -1.18 | -280.65 | -227.78 | -0.90 | -246.15 | -109.3 | -1.87 | -175.0 | -156.16 |
| 21Q3 (8) | -0.31 | 20.51 | -72.22 | -0.26 | 21.21 | -23.81 | -0.68 | -83.78 | -88.89 |
| 21Q2 (7) | -0.39 | -2050.0 | -425.0 | -0.33 | -3.13 | -3200.0 | -0.37 | -1950.0 | -105.56 |
| 21Q1 (6) | 0.02 | 105.56 | 106.67 | -0.32 | 25.58 | -300.0 | 0.02 | 102.74 | 106.67 |
| 20Q4 (5) | -0.36 | -100.0 | -12.5 | -0.43 | -104.76 | 0 | -0.73 | -102.78 | 68.26 |
| 20Q3 (4) | -0.18 | -250.0 | 0.0 | -0.21 | -2000.0 | 0.0 | -0.36 | -100.0 | 0.0 |
| 20Q2 (3) | 0.12 | 140.0 | 0.0 | -0.01 | -106.25 | 0.0 | -0.18 | 40.0 | 0.0 |
| 20Q1 (2) | -0.30 | 6.25 | 0.0 | 0.16 | 0 | 0.0 | -0.30 | 86.96 | 0.0 |
| 19Q4 (1) | -0.32 | 0.0 | 0.0 | -0.00 | 0.0 | 0.0 | -2.30 | 0.0 | 0.0 |
| 年/月 | 營收 | 月增率(%) | 去年同期年增率(%) | 累計營收 | 累計營收年增率(%) | 近三月累計營收 | 存貨銷售比 | 自結稅前EPS | 自結稅前累計EPS | 備註(年增率變動50%需說明原因) |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024/11 | 0.57 | 37.01 | 1.37 | 5.63 | 30.13 | 1.43 | N/A | . | ||
| 2024/10 | 0.42 | -4.8 | -2.66 | 5.06 | 34.44 | 1.36 | N/A | . | ||
| 2024/9 | 0.44 | -12.77 | -29.25 | 4.64 | 39.22 | 1.39 | 8.15 | . | ||
| 2024/8 | 0.5 | 13.55 | 1.57 | 4.21 | 54.86 | 1.39 | 8.15 | . | ||
| 2024/7 | 0.44 | 0.72 | -3.64 | 3.7 | 66.75 | 1.34 | 8.42 | . | ||
| 2024/6 | 0.44 | -3.79 | 35.72 | 3.26 | 85.15 | 1.47 | 7.95 | . | ||
| 2024/5 | 0.46 | -20.1 | 51.19 | 2.82 | 96.3 | 1.78 | 6.55 | . | ||
| 2024/4 | 0.57 | -24.04 | 37.59 | 2.36 | 108.34 | 1.92 | 6.07 | . | ||
| 2024/3 | 0.75 | 26.09 | 232.42 | 1.79 | 149.34 | 1.79 | 6.78 | 因肌肉注射劑型美國FDA發出拒絕提交信函，本季重新評估未來預計銷售數量，故本月營收有包括部分合約負債調整認列。 | ||
| 2024/2 | 0.6 | 36.29 | 147.4 | 1.04 | 110.99 | 1.62 | 7.47 | . | ||
| 2024/1 | 0.44 | -25.46 | 75.74 | 0.44 | 75.74 | 1.59 | 7.63 | . | ||
| 2023/12 | 0.59 | 4.18 | -39.22 | 4.92 | -13.1 | 1.58 | 8.0 | - | ||
| 2023/11 | 0.56 | 31.55 | -57.28 | 4.33 | -7.71 | 1.61 | 7.84 | 因去年度與Thera EU 中止合約，相關合約負債轉列收入，導致去年度收入較高 | ||
| 2023/10 | 0.43 | -30.8 | -57.25 | 3.76 | 11.73 | 1.54 | 8.19 | 因去年度與Thera EU 中止合約，相關合約負債轉列收入，導致去年度收入較高 | ||
| 2023/9 | 0.62 | 25.21 | 60.86 | 3.34 | 41.02 | 1.58 | 8.54 | 本月營收包含CDMO...等業務 | ||
| 2023/8 | 0.5 | 7.72 | 65.53 | 2.72 | 37.15 | 1.28 | 10.52 | . | ||
| 2023/7 | 0.46 | 41.89 | 63.68 | 2.22 | 32.1 | 1.09 | 12.39 | . | ||
| 2023/6 | 0.32 | 7.16 | 18.27 | 1.76 | 25.76 | 1.04 | 12.95 | . | ||
| 2023/5 | 0.3 | -27.29 | -3.4 | 1.44 | 27.58 | 0.94 | 14.29 | - | ||
| 2023/4 | 0.42 | 83.5 | 2.5 | 1.13 | 39.52 | 0.88 | 15.27 | . | ||
| 2023/3 | 0.23 | -6.15 | 75.89 | 0.72 | 76.45 | 0.72 | 19.15 | . | ||
| 2023/2 | 0.24 | -3.18 | 68.2 | 0.49 | 76.72 | 1.46 | 9.42 | . | ||
| 2023/1 | 0.25 | -74.22 | 85.83 | 0.25 | 85.83 | 2.54 | 5.41 | . | ||
| 2022/12 | 0.97 | -26.77 | 419.55 | 5.66 | 36.88 | 3.29 | 4.2 | 差異主要原因係將部分帳列合約負債權利金調整轉列營業收入認列所致。 | ||
| 2022/11 | 1.32 | 31.65 | 526.47 | 4.69 | 18.82 | 2.71 | 5.1 | 差異主要原因係本月認列部分Theratechnology歐洲權利金 | ||
| 2022/10 | 1.0 | 160.39 | 177.92 | 3.37 | -9.83 | 1.69 | 8.18 | 差異主要原因係本月認列部分Theratechnology歐洲權利金 | ||
| 2022/9 | 0.39 | 28.85 | 37.55 | 2.37 | -29.93 | 0.97 | 15.52 | - | ||
| 2022/8 | 0.3 | 6.52 | -3.04 | 1.98 | -36.04 | 0.85 | 17.55 | . | ||
| 2022/7 | 0.28 | 2.52 | -12.83 | 1.68 | -39.69 | 0.87 | 17.27 | - | ||
| 2022/6 | 0.27 | -12.47 | -41.07 | 1.4 | -43.21 | 0.99 | 14.83 | . | ||
| 2022/5 | 0.31 | -22.84 | -39.55 | 1.13 | -43.71 | 0.85 | 17.36 | - | ||
| 2022/4 | 0.41 | 214.89 | -28.7 | 0.81 | -45.16 | 0.68 | 21.7 | . | ||
| 2022/3 | 0.13 | -10.25 | 46.73 | 0.41 | -55.43 | 0.41 | 37.03 | 本公司規畫預計111年4月起開始銷售三星生物SBL生產之存貨給Theratechnologies | ||
| 2022/2 | 0.14 | 6.95 | -65.11 | 0.28 | -66.31 | 0.46 | 32.45 | . | ||
| 2022/1 | 0.13 | -27.93 | -67.5 | 0.13 | -67.5 | 0.53 | 28.33 | 歐洲銷售因會計認列時點調整遞延至Theratech實際銷售時認列收入，故ㄧ月銷售Theratech的一批次Trogarzo 暫不認列 | ||
| 2021/12 | 0.19 | -11.71 | -53.83 | 4.13 | -42.77 | 0.76 | 15.4 | . | ||
| 2021/11 | 0.21 | -41.59 | -62.31 | 3.95 | -42.12 | 0.85 | 13.7 | . | ||
| 2021/10 | 0.36 | 28.88 | -36.7 | 3.74 | -40.31 | 0.95 | 12.29 | . | ||
| 2021/9 | 0.28 | -9.17 | 6855.83 | 3.38 | -40.67 | 0.91 | 12.67 | . | ||
| 2021/8 | 0.31 | -4.22 | -43.45 | 3.1 | -45.56 | 1.1 | 10.54 | . | ||
| 2021/7 | 0.32 | -30.68 | -66.36 | 2.79 | -45.78 | 1.31 | 8.85 | . | ||
| 2021/6 | 0.46 | -10.22 | 0.92 | 2.46 | -41.07 | 1.55 | 7.57 | - | ||
| 2021/5 | 0.52 | -8.99 | -18.9 | 2.0 | -46.27 | 1.17 | 10.0 | - | ||
| 2021/4 | 0.57 | 548.05 | -17.66 | 1.48 | -51.94 | 1.07 | 11.0 | . | ||
| 2021/3 | 0.09 | -78.66 | -92.62 | 0.91 | -61.84 | 0.91 | 13.72 | 請參閱110年4月7日重大訊息「三月營收公告補充說明」 | ||
| 2021/2 | 0.41 | -0.36 | 38.32 | 0.82 | -31.37 | 1.23 | 10.19 | - | ||
| 2021/1 | 0.41 | 2.38 | -54.3 | 0.41 | -54.3 | 1.38 | 9.1 | . | ||
| 2020/12 | 0.4 | -27.92 | 0.0 | 7.22 | 2.6 | 1.53 | 8.21 | . | ||
| 2020/11 | 0.56 | -1.92 | -43.36 | 6.82 | -3.12 | 1.13 | 11.1 | - | ||
| 2020/10 | 0.57 | 14064.5 | -47.95 | 6.26 | 3.44 | 1.12 | 11.24 | - | ||
| 2020/9 | 0.0 | -99.26 | -99.42 | 5.69 | 14.82 | 1.51 | 7.63 | 因疫情影響TH庫存調整未採購，營收屬Q3折讓調整，與去年度比較今年營收成長15%目標不變。季底匯率評價調減本月大部分合併營收。 | ||
| 2020/8 | 0.55 | -43.03 | -36.11 | 5.69 | 33.63 | 1.96 | 5.85 | 本月營收為出貨給Theratechnologies用於歐洲未來銷售使用，先以較低之約定價格出售，待確認實際銷售價格時再予以調整。 | ||
| 2020/7 | 0.96 | 108.01 | 69.86 | 5.14 | 51.15 | 2.06 | 5.59 | . | ||
| 2020/6 | 0.46 | -27.86 | -8.77 | 4.18 | 47.43 | 1.79 | 5.8 | Q2因疫情美國各地封城影響，新病患人數減少，TH庫存調整本月未下訂單，本月營收 46,069仟元屬Q1及Q2銷貨折讓與實際數差異調整。 | ||
| 2020/5 | 0.64 | -7.6 | 1.14 | 3.72 | 59.61 | 2.52 | 4.12 | . | ||
| 2020/4 | 0.69 | -41.92 | 65.75 | 3.08 | 81.32 | 2.18 | 4.76 | . | ||
| 2020/3 | 1.19 | 299.93 | 79.42 | 2.39 | 86.37 | 2.39 | 4.24 | . | ||
| 2020/2 | 0.3 | -67.08 | 29.01 | 1.2 | 93.82 | 1.2 | 8.45 | 本月份Theratechnologies尚在進行調整庫存並未下採購訂單，本月中裕銷貨收入為2019第四季暫估銷售折讓與實際數差異調整 | ||
| 2020/1 | 0.9 | 0.0 | 132.2 | 0.9 | 132.2 | 0.0 | N/A | . | ||
| 2019/12 | 0.0 | -100.0 | -100.0 | 7.04 | 192.11 | 0.0 | N/A | 本月無營收主要係Theratechnologies進行存貨調整，108/12無訂貨，將遞延至109年開始訂貨，細節請參閱12/19重大訊息說明 |
